Extended postpartum intimate partner violence and its associated factors among Iranian women: Community‐based cross‐sectional study design
International Journal of Gynecology & Obstetrics · 2025-02 · 168 (2) · 535-544
DOI: 10.1002/ijgo.15907 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Gynecology & Obstetrics, online erschienen am 10.09.2024. Verfasst von Fatemeh Ghelichkhani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Intimate Partner Violence, Postpartum Period. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben.
Abstract (Originalsprache)
Objective
The purpose of this study was to determine the prevalence of different types of intimate partner violence (IPV) and factors associated with it during the postpartum period.
Methods
In this cross‐sectional study, 428 women were enrolled from 10 health centers in the south of Tehran, Iran, between April 2023 and October 2023. We used a sociodemographic questionnaire, Conflict Tactics Scale (CTS2), the short form of the Connor‐Davidson Resilience Scale (CD‐RISC), and the Depression, Anxiety and Stress Scale (DASS‐21) for data collection. Multivariate binary logistic regression was used to determine demographic and psychological predictors of IPV after childbirth.
Results
Approximately two‐thirds of women (n=285, 66.6%) experienced IPV within 1 year of childbirth. Psychological aggression (n= 276, 64.5%) was the most common type of IPV, whereas injury (n=96, 22.4%) was the least common. Additionally, one in three women experienced physical assault (n= 134, 31.3%), and over one‐third experienced sexual coercion (n= 152, 35.5%). Predictor factors of IPV during the postpartum period were: insufficient family income (adjusted odds ratio [aOR] 4.52, 95% confidence interval [CI] 1.24–15.28), husband's smoking (aOR 3.17, 95% CI 1.70–5.92), history of IPV in pregnancy (aOR 2.44, 95% CI 1.33–4.50), number of children (aOR 3.02, 95% CI 1.79–5.10), and depression (aOR 1.2, 95% CI 1.08–1.14). On the other hand, protective factors of IPV during the postpartum period were: longer marriage duration (aOR 0.85, 95% CI 0.77–0.93) and greater resilience (aOR 0.95, 95% CI 0.90–0.99).
Conclusion
IPV is prevalent 1 year after childbirth. Healthcare providers should implement a thorough screening program to identify risk and protective factors related to postpartum IPV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Midwifery, Imam Sajad Hospital, Iran University of Medical Sciences, Tehran, Iran.
- Department of Public Health, School of Nursing, Aja University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Masoumeh Namazi
Zitieren
APA
Ghelichkhani, F., Behboodi Moghadam, Z., Zareiyan, A., & Namazi, M. (2025). Extended postpartum intimate partner violence and its associated factors among Iranian women: Community‐based cross‐sectional study design. International Journal of Gynecology & Obstetrics, 168(2), 535-544. https://doi.org/10.1002/ijgo.15907
Vancouver
Ghelichkhani F, Behboodi Moghadam Z, Zareiyan A, Namazi M. Extended postpartum intimate partner violence and its associated factors among Iranian women: Community‐based cross‐sectional study design. International Journal of Gynecology & Obstetrics. 2025;168(2):535-544. doi:10.1002/ijgo.15907
BibTeX
@article{Ghelichkhani2025,
author = {Ghelichkhani, Fatemeh and Behboodi Moghadam, Zahra and Zareiyan, Armin and Namazi, Masoumeh},
title = {Extended postpartum intimate partner violence and its associated factors among Iranian women: Community‐based cross‐sectional study design},
journal = {International Journal of Gynecology & Obstetrics},
year = {2025},
volume = {168},
number = {2},
pages = {535--544},
doi = {10.1002/ijgo.15907}
}
EUVIMED